Inventiva Pharma (Euronext Paris: IVA), a Paris, France-based biopharmaceutical company, raised €35.5M in funding.
Sofinnova Partners led the round investing €10M via its newly created Sofinnova Crossover I Fund. A representative of Sofinnova Partners shall be designated at the Board of directors of Inventiva.
The company intends to use the funds to advance its portfolio of compounds in the clinic, in particular its lead compound, lanifibranor, through preparatory studies towards a Phase III trial for the treatment of NASH and of systemic sclerosis an orphan disease, and to develop its second program, odiparcil, a drug candidate for the treatment of multiple forms of mucopolysaccharidosis.
Inventiva is a biopharmaceutical company specialized in the development of treatments for fibroticand orphan diseases, such as Non Alcoholic Steato Hepatitis (NASH), systemic scleroderma (SSc) and mucopolysaccharidosis (MPS). Inventiva has a technology platform built on its extensive knowledge of the mechanisms of fibrosis, a chemical library of over 240,000 molecules and cell models, including patient cells, helping accelerate the discovery of new mechanisms and therapeutic candidates for the treatment of fibrotic diseases, orphan diseases and cancers.